- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2730-664X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders ; volume:2 ; number:1 ; day:11 ; month:7 ; year:2022 ; pages:1-7 ; date:12.2022
Communications medicine ; 2, Heft 1 (11.7.2022), 1-7, 12.2022
- Creator
-
Lake, Douglas F.
Roeder, Alexa J.
Gonzalez-Moa, Maria J.
Koehler, Megan
Kaleta, Erin
Jasbi, Paniz
Vanderhoof, John
McKechnie, Davis
Forman, Jack
Edwards, Baylee A.
Seit-Nebi, Alim
Svarovsky, Sergei
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s43856-022-00151-2
- URN
-
urn:nbn:de:101:1-2022091923113601583525
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lake, Douglas F.
- Roeder, Alexa J.
- Gonzalez-Moa, Maria J.
- Koehler, Megan
- Kaleta, Erin
- Jasbi, Paniz
- Vanderhoof, John
- McKechnie, Davis
- Forman, Jack
- Edwards, Baylee A.
- Seit-Nebi, Alim
- Svarovsky, Sergei
- SpringerLink (Online service)
Other Objects (12)
P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
Predicting IVF outcome in poor ovarian responders
Broadly Neutralizing Antibodies for HIV Eradication
Non-neutralizing antibodies and vaccine-induced protection
Eliciting neutralizing antibodies with gp120 outer domain
Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
The expanding array of HIV broadly neutralizing antibodies
Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
Rapid detection of anti-Vaccinia virus neutralizing antibodies
SHIVs, monkeys, and anti-HIV-1 neutralizing antibodies
Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
Predicting IVF outcome in poor ovarian responders
Broadly Neutralizing Antibodies for HIV Eradication
Non-neutralizing antibodies and vaccine-induced protection
Eliciting neutralizing antibodies with gp120 outer domain
Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
The expanding array of HIV broadly neutralizing antibodies
Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
Rapid detection of anti-Vaccinia virus neutralizing antibodies
SHIVs, monkeys, and anti-HIV-1 neutralizing antibodies
Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
Predicting IVF outcome in poor ovarian responders
Broadly Neutralizing Antibodies for HIV Eradication
Non-neutralizing antibodies and vaccine-induced protection
Eliciting neutralizing antibodies with gp120 outer domain
Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
The expanding array of HIV broadly neutralizing antibodies
Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
Rapid detection of anti-Vaccinia virus neutralizing antibodies
SHIVs, monkeys, and anti-HIV-1 neutralizing antibodies